MRTX - Mirati Therapeutics' adagrasib shows encouraging action in anti-tumor activity

Mirati Therapeutics (MRTX) reports preliminary results from its mutant KRAS selective inhibitor programs. The results included updated clinical data of adagrasib (MRTX849), a KRAS G12C inhibitor, presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics and initial preclinical in vivo data of MRTX1133, selective and potent KRAS G12D inhibitor.The adagrasib showed deep and durable anti-tumor activity in non-small cell lung cancer ((NSCLC)), colorectal cancer ((CRC)) and other solid tumors.Efficacy data from Phase 1/1b cohort and Phase 2 registration-enabling cohort (n=51):A 45% confirmed objective response rate ((ORR)) for adagrasib as a monotherapy in advanced NSCLC was observed. 65% of patients remain on treatment.70% (16/23) of responders had a best tumor response greater than 40% with 3.6 months median duration of follow-up. Disease control rate ((DCR)) was 96%.Efficacy data from the Phase 1/1b cohort (n=14): Median duration of treatment 8.2 months with confirmed ORR of 43% and 100% DCR. 50% of

For further details see:

Mirati Therapeutics' adagrasib shows encouraging action in anti-tumor activity